Bio-Rad Laboratories, Inc. $BIO Shares Sold by Park Avenue Securities LLC

Park Avenue Securities LLC lessened its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 2,321 shares of the medical research company’s stock after selling 70 shares during the period. Park Avenue Securities LLC’s holdings in Bio-Rad Laboratories were worth $560,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Quarry LP acquired a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $29,000. Curat Global LLC acquired a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $34,000. Allworth Financial LP raised its stake in Bio-Rad Laboratories by 260.0% during the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 104 shares during the period. UMB Bank n.a. raised its stake in Bio-Rad Laboratories by 89.8% during the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 79 shares during the period. Finally, Headlands Technologies LLC raised its stake in Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after purchasing an additional 139 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.5%

NYSE BIO opened at $271.80 on Monday. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $7.35 billion, a PE ratio of 23.17 and a beta of 0.95. The firm’s fifty day simple moving average is $278.05 and its 200-day simple moving average is $253.55.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The business had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. During the same period in the prior year, the business posted $3.11 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 22nd. Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.